Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Raloxifene].

E F Eriksen1

  • 1Arhus Amtssygehus, medicinsk-endokrinologisk afdeling C.

Ugeskrift for Laeger
|August 30, 2000
PubMed
Summary
This summary is machine-generated.

Raloxifene, a selective estrogen receptor modulator (SERM), improves bone density and reduces fracture risk. It also lowers breast cancer risk but carries a similar risk of venous thrombosis as estrogen.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of hormone replacement therapy on bone formation quality and mineralization regulation mechanisms in early postmenopausal women.

Bone reports·2021
Same author

Skeletal effects of plyometric exercise and metformin in ovariectomized rats.

Bone·2019
Same author

Determinants of trabecular bone score and prevalent vertebral fractures in women with fragility fractures: a cross-sectional sub-study of NoFRACT.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Changes in bone quality after Roux-en-Y gastric bypass: A prospective cohort study in subjects with and without type 2 diabetes.

Bone·2019
Same author

Enhanced angiogenesis and increased bone turnover characterize bone marrow lesions in osteoarthritis at the base of the thumb.

Bone & joint research·2018
Same author

Serum parathyroid hormone is associated with increased cortical porosity of the inner transitional zone at the proximal femur in postmenopausal women: the Tromsø Study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026
Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026
Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026
Same journal

[Fitness].

Ugeskrift for laeger·2026
Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026
Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Oncology

Context:

  • Selective estrogen receptor modulators (SERMs) represent a class of drugs with tissue-specific effects.
  • Raloxifene interacts with estrogen receptor alpha and beta, eliciting distinct postreceptor responses compared to endogenous estrogens.

Purpose:

  • To elucidate the tissue-specific effects of raloxifene.
  • To evaluate raloxifene's impact on bone mass, fracture risk, breast cancer incidence, endometrial changes, and cardiovascular markers.

Summary:

  • Raloxifene significantly increases bone mineral density by 2-3% and reduces vertebral fractures by 30-50%.
  • The drug demonstrates a substantial risk reduction for breast cancer (76% after four years) and induces an atrophic endometrium without associated bleeding or increased endometrial cancer risk.

Related Experiment Videos

  • Positive effects on plasma lipids were observed, though their impact on myocardial infarction and cardiovascular mortality remains undetermined.

    • Impact:

    • Raloxifene offers significant benefits for bone health and breast cancer prevention in postmenopausal women.
    • Understanding its differential effects compared to estrogen is crucial for therapeutic applications.
    • Further research is needed to clarify the cardiovascular implications of raloxifene's lipid-modulating effects.